Multidisciplinary Management of Advanced Kidney Cancer

Restricted access

A number of therapeutic options are available for the treatment of advanced kidney cancer, including targeted therapy, immunotherapy, and nephrectomy. Choice of therapy for advanced kidney cancer is guided by risk stratification. Immunotherapy combinations are generally superior to vascular endothelial growth factor -based monotherapy, and overall survival rates continue to increase substantially. With new systemic therapy options, additional improvements have been noted in durable responses to treatment and in quality of life. Nephrectomy remains an important consideration in selected patients, particularly those with minimal burden of metastatic disease. Managing the adverse events of treatment of advanced kidney cancer requires close attention and multidisciplinary collaboration.

Disclosures: Dr. LaGrange has disclosed that he receives grant/research support from Boston Scientific, a consulting fee from Integer, and is a scientific advisor for Manzanita Pharmaceuticals. Dr. Michaelson has disclosed that he is a scientific advisor for Eisai Inc, Exelixis Inc, and Pfizer Inc. Ms. Tetzlaff has disclosed that she has no relevant relationships.

Correspondence: Chad A. LaGrange, MD, University of Nebraska, 984110 Nebraska Medical Center, Omaha, NE 68198. Email:; M. Dror Michaelson, MD, PhD, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7E, Boston, MA 02114. Email:; and Colleen H. Tetzlaff, MHS, PA-C, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Email:
  • 1.

    Mejean A, Thezenas S, Chevreau C, Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417427.

  • 2.

    Bex A, Mulders P, Jewett M, Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib. The SURTIME randomized trial. JAMA Oncol 2019;5:164170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Motzer R, Rini B, McDermott DF, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled phase3 trial. Lancet Oncol 2019;20:13701385.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Rini B, Plimack EP, Stus V, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:11161127.

  • 5.

    Motzer RJ, Penkov K, Haanen J, Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma. N Engl J Med 2019;380:11031115.

  • 6.

    Motzer RJ, Jonasch E, Agarwal N, NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2.2020. Accessed March 2, 2020. To view the most recent version, visit

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 47 47 47
PDF Downloads 12 12 12
EPUB Downloads 0 0 0